Daily Endocrinology Research Analysis
Today’s top endocrinology-related papers span prevention, mechanism, and therapeutics: a 183,000-participant prospective cohort defines risk-stratified non-HDL-C targets linked to lower ASCVD and mortality; a mechanistic study shows labile iron controls adipose CD8+ T cell inflammatory tone in obesity via NRF2/iron-handling nodes; and real-world data support metformin’s safety and cardiometabolic benefits in solid organ transplant recipients with diabetes.
Summary
Today’s top endocrinology-related papers span prevention, mechanism, and therapeutics: a 183,000-participant prospective cohort defines risk-stratified non-HDL-C targets linked to lower ASCVD and mortality; a mechanistic study shows labile iron controls adipose CD8+ T cell inflammatory tone in obesity via NRF2/iron-handling nodes; and real-world data support metformin’s safety and cardiometabolic benefits in solid organ transplant recipients with diabetes.
Research Themes
- Risk-stratified lipid targets and outcomes
- Immunometabolism and iron homeostasis in obesity
- Therapeutics in complex populations (post-transplant diabetes)
Selected Articles
1. Association of non-high-density lipoprotein cholesterol with atherosclerotic cardiovascular disease and all-cause mortality in Chinese populations with different baseline risks: A prospective cohort study.
Across 183,224 adults stratified by baseline cardiovascular risk, lower non-HDL-C thresholds (<140, <120, and <100 mg/dL for low-, primary-, and secondary-prevention groups, respectively) were associated with reduced ASCVD and all-cause mortality. Sustained low non-HDL-C conferred sizable risk reductions, supporting risk-stratified targets.
Impact: Provides large-scale, time-updated evidence to refine non-HDL-C targets by baseline risk, directly informing preventive lipid management strategies.
Clinical Implications: Adopt lower non-HDL-C targets as baseline risk increases (<140, <120, <100 mg/dL) and prioritize sustained lowering over time to reduce ASCVD and mortality.
Key Findings
- Non-HDL-C thresholds associated with lower risk: <140 mg/dL (low risk), <120 mg/dL (primary prevention), <100 mg/dL (secondary prevention).
- Sustained lower non-HDL-C associated with 43% reduced ASCVD risk in low-risk and 27% in primary prevention populations.
- In secondary prevention, sustained lower non-HDL-C was linked to 25% lower all-cause mortality.
- Time-varying Cox models captured associations using repeated non-HDL-C measurements.
Methodological Strengths
- Very large, prospectively followed cohorts with stratification by baseline risk.
- Use of time-varying Cox models and repeated lipid measurements to reduce bias.
Limitations
- Observational design inherently limits causal inference and may retain residual confounding.
- Follow-up duration and event adjudication details were not specified in the abstract; generalizability beyond Chinese populations requires caution.
Future Directions: Validate risk-stratified non-HDL-C targets in multi-ethnic cohorts and test target-driven strategies in pragmatic trials.
BACKGROUND: This study, for the first time, stratified a larger sample size of participants according to the Framingham Risk Score and applied a fine-grained classification of non-high-density lipoprotein cholesterol (non-HDL-C) in 20 mg/dL increments, aiming to further analyze the associations of baseline non-HDL-C and its changes with atherosclerotic cardiovascular disease (ASCVD) and all-cause mortality across different baseline risk populations. METHODS: The study included 90,072 low-risk individuals, 77,499 primary prevention individuals, and 15,653 secondary prevention individuals. Using time-varying Cox proportional hazards regression models, we assessed the association of non-HDL-C levels with the risks of ASCVD and all-cause mortality across different baseline risk populations. Furthermore, based on non-HDL-C levels in 2 consecutive measurements, we evaluated the association of changes in non-HDL-C with the risks of ASCVD and all-cause mortality. RESULTS: This study found that non-HDL-C levels below 140 mg/dL in low-risk populations, below 120 mg/dL in primary prevention populations, and below 100 mg/dL in secondary prevention populations were significantly associated with a reduced risk of ASCVD and all-cause mortality. Furthermore, sustained lower non-HDL-C was associated with a 43% reduced risk of ASCVD in low-risk populations and a 27% reduced risk in primary prevention populations, whereas in secondary prevention populations it corresponded to a 25% reduced risk of all-cause mortality. CONCLUSIONS: As baseline risk levels increase, lower non-HDL-C levels are significantly associated with reduced risks of ASCVD and all-cause mortality. Moreover, sustained lower non-HDL-C levels are associated with a significant decrease in ASCVD and all-cause mortality risks across different baseline risk populations.
2. Obesity rewires CD8+ T cell iron metabolism in adipose tissue to fuel metabolic inflammation.
Adipose CD8+ T cells in obesity accumulate labile iron, boosting ROS and IFNγ. Genetic perturbations (Ncoa4, Fth1) and CD8-specific NRF2 activation demonstrate causality and therapeutic leverage, with NRF2 overexpression attenuating adipose inflammation and metabolic dysfunction.
Impact: Reveals a modifiable iron–NRF2 axis in tissue-resident T cells as a driver of metabolic inflammation, opening a mechanistically grounded immunometabolic therapeutic avenue.
Clinical Implications: Targeting iron handling or activating NRF2 in T cells could represent novel strategies to reduce adipose inflammation and metabolic complications of obesity, pending translational studies.
Key Findings
- Adipose CD8+ T cells have elevated labile iron and mitochondrial Fe2+, driving ROS and IFNγ production in obesity.
- Weight loss normalizes CD8+ T cell iron metabolism in adipose tissue.
- Ncoa4 knockout reduces labile iron, blunting ROS/IFNγ; Fth1 knockout increases Fe2+/ROS and IFNγ.
- CD8+ T cell-specific NRF2 activation restores iron homeostasis and suppresses adipose inflammation; NRF2 overexpression attenuates metabolic dysfunction.
Methodological Strengths
- Mechanistic depth with complementary genetic perturbations (Ncoa4, Fth1, NRF2) in CD8+ T cells.
- Convergent evidence across obesity, weight loss, and functional readouts (ROS, IFNγ, inflammation, metabolic outcomes).
Limitations
- Preclinical models; human validation and doseable therapeutic approaches are required.
- Quantitative sample sizes and experimental durations were not specified in the abstract.
Future Directions: Translate the iron–NRF2 axis to human adipose T cells, define biomarkers of CD8+ iron load, and test pharmacologic NRF2/iron-modulating strategies.
Sufficient nutrient supply is important for the maintenance of non-lymphoid tissue resident CD8+ T cell homeostasis, but the role of labile iron remains unclear. Here, we find adipose tissue CD8+ T cells exhibit elevated labile iron and mitochondrial Fe2+ compared to splenic counterparts, driving high ROS and IFNγ production. In obesity, an increase in Fe2+ influx into mitochondria enhances adipose tissue CD8+ cell functions, but weight loss normalizes CD8+ cell iron metabolism. Ncoa4 knockout reduces labile iron, blunting ROS and IFNγ production, while Fth1 knockout elevates Fe2+ and ROS, elevating IFNγ production. CD8+ cell-specific activation of NRF2 restores iron homeostasis by upregulating ferritin and promoting oxidative detoxification, suppressing adipose tissue CD8+ T cell accumulation and IFNγ production. Finally, NRF2 overexpression in CD8+ T cells attenuates obesity-related adipose tissue inflammation and metabolic disorders. These results highlight the crucial role of labile iron supply in adipose tissue CD8+ T cell homeostasis.
3. Real-World Evidence for Metformin Use in Solid Organ Transplant Recipients Living With Diabetes.
In a 1:1 matched retrospective cohort of 938 solid organ transplant recipients with type 2 diabetes, metformin use correlated with lower MACE (aHR 0.77) and all-cause mortality (aHR 0.52), and reduced graft dysfunction among kidney recipients, without apparent safety compromise.
Impact: Addresses a high-risk, under-studied population and supports broader use of metformin post-transplant with favorable cardiovascular, renal, and survival outcomes.
Clinical Implications: Consider metformin in carefully selected transplant recipients with type 2 diabetes, with monitoring for renal function and drug interactions; prospective trials should refine indications.
Key Findings
- Metformin use associated with lower MACE (adjusted HR 0.77, 95% CI 0.61-0.98).
- All-cause mortality significantly lower with metformin (HR 0.52, 95% CI 0.38-0.71).
- Among kidney recipients, reduced risk of severe graft dysfunction with metformin.
- Favorable metabolic effects without apparent safety signals in this real-world cohort.
Methodological Strengths
- Matched cohort design across multiple organ types with adjusted hazard models.
- Large real-world dataset reflecting routine clinical practice.
Limitations
- Retrospective observational design susceptible to residual confounding and selection bias.
- Follow-up duration and dosing/exposure details not specified in the abstract; prospective confirmation needed.
Future Directions: Prospective, ideally randomized studies to confirm benefits, define renal function thresholds, and assess interactions with immunosuppressants.
OBJECTIVE: Metformin is a widely used, safe, and effective antidiabetic agent; however, its use in solid organ transplant (SOT) recipients has been limited. We aimed to evaluate the safety and cardiovascular, renal, and metabolic outcomes associated with metformin use in a large, real-world cohort of SOT recipients living with diabetes. METHODS: We conducted a retrospective matched-cohort study of adult SOT recipients (kidney, liver, lung, and heart) with pre-existing type 2 diabetes using data from a large health care organization. Metformin users (≥2 prescriptions post-transplant) were 1:1 matched to nonusers by age, sex, and organ type. Primary outcomes included major adverse cardiovascular events, heart failure, all-cause mortality, and severe renal dysfunction (estimated glomerular filtration rate ≤15 mL/min/1.73 m RESULTS: We included 938 matched patients (66% kidney, 14% liver, 16% lung, and 4% heart). Metformin use was associated with a lower risk of major adverse cardiovascular events (adjusted hazard ratio [HR] 0.77, 95% CI 0.61-0.98, P = .031) and all-cause mortality (HR 0.52, 95% CI 0.38-0.71, P < .001). In kidney recipients, metformin was associated with reduced risk of graft dysfunction (estimated glomerular filtration rate <15 mL/min/1.73 m CONCLUSION: In SOT recipients living with diabetes, metformin use was associated with improved survival, cardiovascular and renal outcomes, and favorable metabolic effects without compromising safety. These findings support the cautious use of metformin in selected transplant recipients. Prospective studies are warranted.